MX2021015942A - Composiciones y métodos para tratar trastornos del snc. - Google Patents

Composiciones y métodos para tratar trastornos del snc.

Info

Publication number
MX2021015942A
MX2021015942A MX2021015942A MX2021015942A MX2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A MX 2021015942 A MX2021015942 A MX 2021015942A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cns disorders
treating cns
ilib
Prior art date
Application number
MX2021015942A
Other languages
English (en)
Spanish (es)
Inventor
Francesco G Salituro
María Jesús Blanco-Pillado
Marshall Lee Morningstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021015942A publication Critical patent/MX2021015942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MX2021015942A 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc. MX2021015942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867618P 2019-06-27 2019-06-27
PCT/US2020/040153 WO2020264509A1 (en) 2019-06-27 2020-06-29 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
MX2021015942A true MX2021015942A (es) 2022-04-18

Family

ID=71728947

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021015942A MX2021015942A (es) 2019-06-27 2020-06-29 Composiciones y métodos para tratar trastornos del snc.
MX2024009926A MX2024009926A (es) 2019-06-27 2021-12-16 Composiciones y metodos para tratar trastornos del snc.
MX2024009925A MX2024009925A (es) 2019-06-27 2021-12-16 Composiciones y metodos para tratar trastornos del snc.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024009926A MX2024009926A (es) 2019-06-27 2021-12-16 Composiciones y metodos para tratar trastornos del snc.
MX2024009925A MX2024009925A (es) 2019-06-27 2021-12-16 Composiciones y metodos para tratar trastornos del snc.

Country Status (13)

Country Link
US (1) US12552829B2 (cg-RX-API-DMAC7.html)
EP (1) EP3990469A1 (cg-RX-API-DMAC7.html)
JP (2) JP7787635B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038680A (cg-RX-API-DMAC7.html)
CN (1) CN114391019A (cg-RX-API-DMAC7.html)
AR (1) AR119305A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020302748A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026462A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143509A1 (cg-RX-API-DMAC7.html)
IL (1) IL289172A (cg-RX-API-DMAC7.html)
MX (3) MX2021015942A (cg-RX-API-DMAC7.html)
TW (1) TWI896547B (cg-RX-API-DMAC7.html)
WO (1) WO2020264509A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
BR9509764A (pt) 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
CN101585862B (zh) 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
HUE062616T2 (hu) 2011-09-08 2023-11-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítmények és alkalmazásaik
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
SI3705488T1 (sl) 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CA3030420C (en) * 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
AU2018290348B2 (en) * 2017-06-23 2024-04-04 Ayikoe-Guy MENSAH-NYAGAN Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
WO2019041078A1 (en) 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
EP3728285B1 (en) * 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
CN111410678B (zh) 2019-01-08 2023-02-28 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
WO2020210116A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210117A1 (en) * 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
BR112021026447A2 (pt) 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
EP4251634A1 (en) * 2020-11-25 2023-10-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
BR112021026462A2 (pt) 2022-03-15
IL289172A (en) 2022-02-01
WO2020264509A1 (en) 2020-12-30
US20220380405A1 (en) 2022-12-01
CA3143509A1 (en) 2020-12-30
US20230303616A9 (en) 2023-09-28
EP3990469A1 (en) 2022-05-04
AU2020302748A1 (en) 2022-01-06
KR20220038680A (ko) 2022-03-29
MX2024009926A (es) 2024-08-22
US12552829B2 (en) 2026-02-17
JP2025060984A (ja) 2025-04-10
MX2024009925A (es) 2024-08-22
TWI896547B (zh) 2025-09-11
TW202114700A (zh) 2021-04-16
AR119305A1 (es) 2021-12-09
JP7787635B2 (ja) 2025-12-17
JP2022538299A (ja) 2022-09-01
CN114391019A (zh) 2022-04-22

Similar Documents

Publication Publication Date Title
MX2024009925A (es) Composiciones y metodos para tratar trastornos del snc.
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
SA522432955B1 (ar) Kras g12c مثبطات
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
PH12017501326A1 (en) Tgf-� inhibitors
EP4706761A3 (en) Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
MX2023006063A (es) Composiciones y metodos para el tratamiento de trastornos del sistema nervioso central.
EP4484440A3 (en) Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
MX2021007258A (es) Composiciones de esparsentan amorfas.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12021552953A1 (en) Tricyclic compounds
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
SG11201907945YA (en) Azetidine derivative
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
ZA202204251B (en) Compounds and compositions for the treatment of parasitic diseases
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.